BioCryst Pharmaceuticals Files 8-K

TL;DR

BioCryst just filed an 8-K, looks like they signed a big deal.

AI Summary

On October 1, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and reported other events. It also includes financial statements and exhibits.

Why It Matters

This 8-K filing signals a significant event for BioCryst Pharmaceuticals, potentially involving new agreements or material changes that could impact its business operations and financial standing.

Risk Assessment

Risk Level: medium — Material definitive agreements and other events reported on an 8-K can introduce new risks or opportunities that are not yet fully understood by the market.

Key Players & Entities

• BioCryst Pharmaceuticals, Inc. (company) — Registrant
• October 1, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $250,000,000 — Purchaser and received cash proceeds of $250,000,000, subject to customary purchase price ad

Filing Documents

• ef20056247_8k.htm (8-K) — 44KB
• ef20056247_ex10-1.htm (EX-10.1) — 189KB
• ef20056247_ex10-2.htm (EX-10.2) — 231KB
• ef20056247_ex10-3.htm (EX-10.3) — 249KB
• ef20056247_ex10-4.htm (EX-10.4) — 234KB
• ef20056247_ex10-5.htm (EX-10.5) — 147KB
• ef20056247_ex99-1.htm (EX-99.1) — 19KB
• 0001140361-25-036875.txt ( ) — 1461KB
• bcrx-20251001.xsd (EX-101.SCH) — 4KB
• bcrx-20251001_lab.xml (EX-101.LAB) — 21KB
• bcrx-20251001_pre.xml (EX-101.PRE) — 16KB
• ef20056247_8k_htm.xml (XML) — 4KB

01

Item 1.01. Entry into a Material Definitive Agreement In connection with the Transaction, on October 1, 2025, the Company and BioCryst Ireland amended and restated that certain IP Licence Agreement by and between the Company and BioCryst Ireland, dated as of May 13, 2021 (such amended and restated agreement, the " Amended and Restated IP Licence Agreement "). Pursuant to the Amended and Restated IP Licence Agreement, the Company granted to BioCryst Ireland an exclusive license under certain patents, solely to the extent reasonably necessary or useful for the commercialization of ORLADEYO products for use in the Field (as defined in the Amended and Restated IP Licence Agreement) in the Territory (as defined in the Purchase Agreement), and a non-exclusive license under certain know-how, copyrights and other intellectual property, solely to the extent reasonably necessary or useful for the development, manufacture and commercialization of ORLADEYO products for use in the Field in the Territory, in each case subject to the terms and conditions set forth therein. The foregoing description of the Amended and Restated IP Licence Agreement does not purport to be complete and is subject to, and qualified in its entirety by, reference to the full text of the Amended and Restated IP Licence Agreement, a copy of which is filed as Exhibit 10.1 hereto and is incorporated into this Item 1.01 by reference. In connection with the Transaction, on October 1, 2025, the Company and BioCryst Ireland entered into a supply agreement, pursuant to which the Company will be the exclusive supplier of ORLADEYO products to BioCryst Ireland for commercialization for use in the Field in the Territory (the " Supply Agreement "). The foregoing description of the Supply Agreement does not purport to be complete and is subject to, and qualified in its entirety by, reference to the full text of the Supply Agreement, a copy of which is filed as Exhibit 10.2 hereto and is incorporated into this Item

01

Item 8.01. Other Events On October 1, 2025, the Company issued a press release announcing, among other things, the consummation of the Transaction. A copy of the press release is attached as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Amended and Restated IP Licence Agreement, dated as of October 1, 2025, by and between the Company and BioCryst Ireland.* 10.2 Supply Agreement, dated as of October 1, 2025, by and between the Company and BioCryst Ireland.* 10.3 Global Brand and Support Agreement, dated as of October 1, 2025, by and between the Company and BioCryst Ireland.* 10.4 Transition Services Agreement, dated as of October 1, 2025, by and between the Company and BioCryst Ireland.* 10.5 Trademark License Agreement, dated as of October 1, 2025, by and between the Company and BioCryst Ireland.* 99.1 Press Release, dated October 1, 2025, regarding the consummation of the Transaction. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). *The schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of such schedules and exhibits, or any section thereof, to the SEC upon request. 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioCryst Pharmaceuticals, Inc. Dated: October 1, 2025 By: /s/ Alane Barnes Alane Barnes Chief Legal Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR